
Cervical Cancer
Latest News

Toripalimab, Bevacizumab, and Chemo Elicits Responses in Refractory, Recurrent, or Metastatic Cervical Cancer
By Chris Ryan
Latest Videos
More News

Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.

In an interview with Targeted Oncology, David S. Hong, MD, discussed the mark tisotumab vedotin has made on the metastatic cervical cancer landscape thus far.























